(Source: MARKETWIRE)

Drug companies are carefully navigating the current stretch of
industry consolidation as giants merge and promising small firms seek
interested buyers.
With conditional FDA clearance earlier this month, Pfizer and Wyeth
merged in one of the largest corporate marriages of all time. The new
organization will manage a merged portfolio of products that the FDA
described as 'highly complementary.' Despite that promise, however,
concerns remain about the merger's effect on issues ranging from
long-term shareholder value to the retention of talented employees.
"In some ways, mega-deals like this one create more questions than
answers," says Jason Richardson, president of Cutting Edge
Information. "It will be years before we know how effective this
merger actually was."
While the media focuses on large deals such as this one or the
yet-to-close Merck/Schering-Plough merger, most acquisitions lack the
flash to make major headlines. The bulk of M&A activity involves
smaller organizations. The past year has been especially active for
such mergers, according to "Pharmaceutical Mergers and Acquisitions,"
(http://www.cuttingedgeinformation.com/mergers-acquisitions/) a new
report from Cutting Edge Information.
"Pressure from both sides of a deal drives the merger activity we're
seeing," says Richardson. "Larger companies make acquisitions to
position themselves in certain markets and to prepare for patent
expirations. A lot of smaller and startup companies, meanwhile, face
tremendous financial pressure as operating capital dwindles and
access to funding remains tight."
The Cutting Edge Information report covers the drivers and financing
of M&A activity over the past year, and it describes how companies
deal with the most challenging integration problems. With this
report, readers grasp key components of M&A success:
-- Get a feel for the current M&A landscape: learn what drives
acquisition strategies for top companies -- and how other organizations
seek suitors for their own sales.
-- Build an M&A plan that focuses on key goals, avoids costly mistakes,
and realizes deal potential as quickly as possible.
-- Complete integration as quickly as possible to boost productivity and
realize deal potential.
-- Build an integration timeline to avoid common operational and cultural
pitfalls.
-- Clarify roles, responsibilities and career paths to avoid costly
attrition and retain valuable employees.
-- Gather perspectives and predictions on future deals from the very
managers that execute them.
For a complimentary brochure of this report, visit
http://www.cuttingedgeinformation.com/mergers-acquisitions/
CONTACT:
Stephanie Swanson
919-433-0212
Email Contact
SOURCE: Cutting Edge Information
A service of YellowBrix, Inc.